dc.contributor.author | Kefeli, Umut | |
dc.contributor.author | Arslan, Çağatay | |
dc.contributor.author | Yıldırım, Mahmut Emre | |
dc.contributor.author | Işıkdoğan, Abdurrahman | |
dc.contributor.author | Karadurmuş, Nuri | |
dc.contributor.author | Karabulut, Bülent | |
dc.contributor.author | Çubukçu, Erdem | |
dc.contributor.author | Çiçin, İrfan | |
dc.contributor.author | Yalçın, Şuayib | |
dc.contributor.author | Türk, Hacı Mehmet | |
dc.contributor.author | Bilir, Cemil | |
dc.contributor.author | Karaca, Mustafa | |
dc.contributor.author | Artaç, Mehmet | |
dc.contributor.author | Şendur, Mehmet Nahit | |
dc.contributor.author | Alacacıoğlu, Ahmet | |
dc.contributor.author | Tanrıkulu Şimşek, Eda | |
dc.contributor.author | Dane, Faysal | |
dc.contributor.author | Bilici, Ahmet | |
dc.contributor.author | Çevik, Duygu | |
dc.contributor.author | Gümüş, Mahmut | |
dc.date.accessioned | 2021-12-06T12:08:06Z | |
dc.date.available | 2021-12-06T12:08:06Z | |
dc.date.issued | 2021 | en_US |
dc.identifier.citation | Kefeli, U., Arslan, Ç., Yıldırım, M. E., Işıkdoğan, A., Karadurmuş, N., Karabulut, B. ... Gümüş, M. (2021). Real-world treatment outcomes from nationwide ONCO-colon Turkey registry in RAS wild-type patients treated with biologics first-line metastatic colorectal cancer. Journal of Clinical Oncology. https://dx.doi.org/10.1200/JCO.2021.39.15_suppl.e15561 | en_US |
dc.identifier.issn | 0732-183X | |
dc.identifier.issn | 1527-7755 | |
dc.identifier.uri | https://dx.doi.org/10.1200/JCO.2021.39.15_suppl.e15561 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12511/8619 | |
dc.description.abstract | Background: Efficacy of anti-angiogenic and anti-EGFR agents has been demonstrated metastatic colorectal cancer (mCRC). Real-world evidence is especially important to detect the findings of patients outside of clinical trials. It complements together with clinical trials. However, there are a few studies that evaluated these treatments with biologics in the real-world setting. Recognizing the change that has occurred over the years will also shed light on future approaches. Therefore, we aimed to investigate the real-world data of patients with RAS-wild type mCRC. Methods: Medical records from 28 centers were collected for patients diagnosed with RAS wild-type mCRC between January 2016 and April 2019 and were included into the study. Histopathological, molecular and clinical characteristics of the patients were recorded. The treatment duration, response rate, progression-free survival and safety results were determined. Also, changes over the years were compared. Patients were compared according to the first-line biological treatments as anti-EGFR group (Group A and B) (panitumumab and cetuximab) and anti-VEGF group (group C). | en_US |
dc.description.sponsorship | Amgen Ilac Tic Ltd Sti, Turkey | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Lippincott Williams & Wilkins | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Metastatic Colorectal Cancer | en_US |
dc.subject | Treatment Outcomes | en_US |
dc.subject | ONCO-colon Turkey | en_US |
dc.title | Real-world treatment outcomes from nationwide ONCO-colon Turkey registry in RAS wild-type patients treated with biologics first-line metastatic colorectal cancer | en_US |
dc.type | conferenceObject | en_US |
dc.relation.ispartof | Journal of Clinical Oncology | en_US |
dc.department | İstanbul Medipol Üniversitesi, Tıp Fakültesi | en_US |
dc.identifier.volume | 39 | en_US |
dc.identifier.issue | 15 | en_US |
dc.relation.publicationcategory | Konferans Öğesi - Uluslararası - Kurum Öğretim Elemanı | en_US |
dc.identifier.doi | 10.1200/JCO.2021.39.15_suppl.e15561 | en_US |
dc.identifier.wosquality | Q1 | en_US |